CDTX Cidara Therapeutics Inc.

1.94
+0.05  (+3%)
Previous Close 1.89
Open 1.88
Price To Book 1.92
Market Cap 61,205,830
Shares 31,549,397
Volume 44,821
Short Ratio
Av. Daily Volume 542,768
Stock charts supplied by TradingView

NewsSee all news

  1. Cidara Therapeutics to Present New Clinical and Preclinical Data at Two Upcoming Medical Conferences

    SAN DIEGO, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present three

  2. Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

    WASHINGTON, Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven

  3. Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

    SAN DIEGO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Paul Daruwala, chief

  4. Thinking about buying stock in Cidara Therapeutics, Canopy Growth, Generac, Lowe's, or Medicines Co?

    NEW YORK, Sept. 3, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CDTX, CGC, GNRC, LOW, and MDCO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the

  5. Cidara Therapeutics and Mundipharma Form Strategic Partnership to Develop and Commercialize Rezafungin

    Collaboration combines strengths to develop and commercialize life-saving antifungal treatment and prophylaxis, an area of high unmet medical need Mundipharma acquires exclusive rights to develop and commercialize

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due mid-2020.
Rezafungin (CD101) ReSTORE
Candidemia
Phase 2 data released February 21, 2017 - efficacy not evident, Development to be discontinued.
CD101 Topical - RADIANT
Vulvovaginal candidiasis (VVC)
Phase 3 trial pending funding.
Rezafungin (CD101) ReSPECT
Prophylaxis
Phase 2 data released July 29, 2019 - noted all objectives met.
Rezafungin (CD101) STRIVE B
Candidemia

Latest News

  1. Cidara Therapeutics to Present New Clinical and Preclinical Data at Two Upcoming Medical Conferences

    SAN DIEGO, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present three

  2. Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

    WASHINGTON, Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven

  3. Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

    SAN DIEGO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Paul Daruwala, chief

  4. Thinking about buying stock in Cidara Therapeutics, Canopy Growth, Generac, Lowe's, or Medicines Co?

    NEW YORK, Sept. 3, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CDTX, CGC, GNRC, LOW, and MDCO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the

  5. Cidara Therapeutics and Mundipharma Form Strategic Partnership to Develop and Commercialize Rezafungin

    Collaboration combines strengths to develop and commercialize life-saving antifungal treatment and prophylaxis, an area of high unmet medical need Mundipharma acquires exclusive rights to develop and commercialize